vimarsana.com

Page 279 - நோய் எதிர்ப்பு சக்தி டோவர்டீ நிறுவனம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Punjab coronavirus update: 255 fresh Covid-19 cases, 8 more deaths recorded

Read more about Punjab coronavirus update: 255 fresh Covid-19 cases, 8 more deaths recorded on Business Standard. Punjab s Covid-19 caseload mounted to 1,68,734 on Saturday with 255 fresh infections while the death toll surged to 5,439 as eight more people succumbed to the disease

Flowers: Don t use death as a political weapon

The Day - Post-holiday COVID-19 numbers spike in southeastern Connecticut - News from southeastern Connecticut

Norwich public schools will remain in hybrid model next week, while Norwich Free Academy remains in remote learning amid a post-holiday spike in COVID-19 rates in Norwich and some surrounding towns. Both the Uncas Health District and Ledge Light Health District reported that the highest COVID-19 rates for their towns since March occurred at the end of December. During the two-week period from Dec. 20 to Jan. 1, Norwich had a COVID-19 case rate of 82.3 cases per 100,000 population and a positivity rate of 11.5%, according to figures released by the Uncas Health District. The city’s COVID-19 positivity rate had been 10% for the previous two-week period.

Myriad Genetics Receives First Reimbursement Decision for myChoice Diagnostic System in Japan, Enabling Women with Ovarian Cancer to Benefit from Treatment with Zejula

Posted January 8th, 2021 for Myriad SALT LAKE CITY, Jan. 08, 2021 ( ) Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced today that it received its first reimbursement decision for the Myriad myChoice ® Diagnostic System, which helps determine if women with ovarian cancer will benefit from the PARP inhibitor, Zejula ® (niraparib). myChoice was approved by Japan’s Ministry of Health, Labour and Welfare in September 2020 as a companion diagnostic for this indication and the reimbursement decision is now in effect.  “Myriad’s myChoice test is the only one of its kind to be approved for reimbursement in Japan,” said Nicole Lambert, president of Myriad Genetic Laboratories. “This decision further advances precision medicine and helps ensure that more Japanese women have access to the most advanced therapies in their fight against ovarian cancer.”

Welcome To IANS Live - NATION - 26 teachers test Covid positive in Odisha district

Gajapati Chief District Medical Officer (CDMO) Pradip Kumar Patra informed that 26 teachers have tested Covid-19 positive in the district in the last two days. Schools in Mohana block has reported the maximum number of cases at 21, Patra said.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.